Compare BridgeBio Pharma Inc (BBIO) vs Iron Mountain Inc (IRM) Price & Performance

BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.

Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.

Iron Mountain (IRM) trades at $122.37, up 0.72% on the day, showing strong momentum with a 30.2% gain over three months. The stock is in a bullish technical trend, supported by recent earnings beats and positive analyst sentiment. Revenue growth accelerated to $6.90 billion in 2025, though net margins remain thin at 3.76%. Recent news highlights its data center strength and a $1.5 billion debt offering to fund expansion.

Outlook is cautiously optimistic with a consensus price target of $138.67 offering 13% upside. Risks include high debt levels (debt-to-asset ratio of 79.04% in 2025) and margin pressure. The stock appeals for its growth exposure and dividend yield, but investors should weigh leverage concerns against operational momentum.